Interim Data from ImmunoNET Study Demonstrate NP137 Potential to Overcome Resistance to Immune Checkpoint Inhibitors Clinical Trial Design and Interim Results to be Presented at ASCO and ESMO 2025 April 25th, 2025 Lyon, France and Geneva, Switzerland — NETRIS Pharma,...
In addition to non-dilutive financing from BPI France and FONGIT (Switzerland), TheraPPI completes an initial equity financing to advance the development of its lead program targeting ERK/MyD88 interaction, a novel drug target discovered by TheraPPI founders Patricia...
December 12th, 2024 Lyon, France and Geneva, Switzerland — NETRIS Pharma, a leading clinical-stage biopharmaceutical company dedicated to advancing the next generation of molecules targeting cancer resistance, today announced the appointment of Eric Falcand to its...
November 21st, 2024 Lyon, France and Geneva, Switzerland — NETRIS Pharma, a clinical-stage biopharmaceutical company pioneering therapies to overcome resistance in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...
September 4th, 2024 Lyon, France and Geneva, Switzerland — NETRIS Pharma, today announced the appointment Ségolène BISOT-LOCARD, MD, as Chief Medical Officer (CMO), effective September 3rd, 2024. She will serve on the Company’s executive leadership team. “We are...
PULSALYS and TheraPPI Bioscience SAS enter into an exclusive and global license agreement to develop drugs targeting a novel Ras-MAPK pathway protein interaction. August 27, 2024 – Lyon, France TheraPPI Bioscience SAS (“TheraPPI”), a preclinical...
